The Analyst Verdict: Sage Therapeutics In The Eyes Of 13 Experts
Portfolio Pulse from Benzinga Insights
Sage Therapeutics (NASDAQ:SAGE) has been evaluated by 13 analysts, showing a mix of bullish and bearish perspectives. The average 12-month price target is $17.38, a 21.53% decrease from the previous target. Analysts have adjusted their ratings and price targets, reflecting changes in market conditions and company performance. Sage Therapeutics is a clinical-stage biopharmaceutical company focusing on brain health medicines, with significant revenue growth but challenges in asset utilization.
October 04, 2024 | 4:00 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Sage Therapeutics has received mixed analyst ratings, with a significant decrease in the average price target to $17.38. Analysts have adjusted their ratings and price targets, indicating a cautious outlook. Despite strong revenue growth, the company faces challenges in asset utilization.
The decrease in the average price target and the predominance of neutral to somewhat bearish ratings suggest a negative short-term outlook for Sage Therapeutics. The company's strong revenue growth is overshadowed by challenges in asset utilization, leading to cautious analyst sentiment.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100